KalshiVerfügbarkeit prüfenKYC erforderlich2% GebührVerifizierte AuflösungsdatenGrob kalibriertAktuelle implizite WahrscheinlichkeitBefore September 24%-3.0%Führend unter 4 Optionen
Marktqualitat
80 / 100
Hohe Qualität24h-Volumen
1327,4 €
Liquidität
27.466,7 €
Hohe LiquiditätGeld / Brief
24.0% / 25.0%
Spread
4.2%
Mittlerer SpreadMarktdaten
Aktualisiert vor 25 Minuten
24. März 26, 14:001. Sept. 26, 3:59
Trends
Nur virtuelles Guthaben – kein echtes GeldKeine Finanzberatung
Gewähltes Ergebnis
Before September24%
Volumentrend
$1.5k2. Juli25T Daten26. Juli
Verwandte Märkte
New pandemic in 2026?
6231,9 €Ja: 7%
POLYMARKET
POLYMARKET
Hantavirus pandemic in 2026?
3245 €Ja: 3%POLYMARKET
POLYMARKET
Measles cases in 2026?
2546,6 €Above 4000: 39%KALSHI
KALSHI
Ebola pandemic in 2026?
1660,2 €Ja: 4%POLYMARKET
POLYMARKET
When "Will Masking Return"? (widespread mask mandates in the USA)
996,3 €September 2023: 1%MANIFOLD MARKETS
MANIFOLD MARKETSWill the NIH indirect cost cap stick?
879,1 €Ja: 11.4%MANIFOLD MARKETS
MANIFOLD MARKETSIn diesen Themen aktiv
Regeln
If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jul 1, 2026, then the market resolves to Yes.
- The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility.
- Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.
- If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.
- If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Nov 1, 2026, then the market resolves to Yes.
- If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jan 1, 2027, then the market resolves to Yes.